Immune potential of a novel multiple-epitope vaccine to FMDV type Asia 1 in guinea pigs and sheep

Abstract

To develop a safe and efficient recombinant subunit vaccine to foot-and-mouth disease virus (FMDV) type Asia 1 in sheep, a tandem repeated multiple-epitope gene consisting of residues 137-160 and 197-211 of the VP1 gene of FMDV was designed and artificially synthesized. The biologically functional molecule, the ovine IgG heavy constant region (oIgG) as a protein carrier was introduced for design of the multiple-epitope recombinant vaccine and recombinant expression plasmids pET-30a-RE and pET-30a-RE-oIgG were successfully constructed. The recombinant proteins, RE and RE-oIgG, were expressed as a formation of inclusion bodies in E. coli. The immune potential of this vaccine regime in guinea pigs and sheep was evaluated. The results showed that IgG could significantly enhance the immune potential of antigenic epitopes. The recombinant protein RE-oIgG could not only elicit the high levels of neutralizing antibodies and lymphocytes proliferation responses in the vaccinated guinea pigs, but confer complete protection in guinea pigs against virus challenge. Although the recombinant protein RE could not confer protection in the vaccinated animals, it could delay the appearance of the clinical signs and reduce the severity of disease. Inspiringly, the titers of anti-FMDV neutralizing antibodies elicited in sheep vaccinated with RE-oIgG was significantly higher than that for the RE vaccination. Therefore, we speculated that this vaccine formulation may be a promising strategy for designing a novel vaccine against FMDV in the future.

Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle

“…The FMDV-specific antibody titers in immunized pigs and cattle were detected by a liquid-phase-block ELISA (LPB-ELISA) kit as described by Shao et al [38]. Briefly, 50 μL of 2-fold serial dilution of each test serum in duplicate were prepared in U-bottom multiwell plates (Corning, NY, USA).…”

Hollow mesoporous silica nanoparticles as delivery vehicle of foot‐and‐mouth disease virus‐like particles induce persistent immune responses in guinea pigs

“…Then, 0.2 mL aliquots of homologous live virus solution diluted from 10 to 6.5 were subcutaneously and intradermally injected into the interdigital skin of each left back leg of guinea pigs at 14 weeks. The guinea pigs were observed for seven days continuously . The lesion appearing only on the left back leg was considered to as an indicator of partial protection, on both back soles as an indicator of no protection and no lesion on the back as an indicator of total protection.…”

“…The guinea pigs were observed for seven days continuously. 23,24 The lesion appearing only on the left back leg was considered to as an indicator of partial protection, on both back soles as an indicator of no protection and no lesion on the back as an indicator of total protection.…”

Epitope-based vaccine as a universal vaccination strategy against Toxoplasma gondii infection: A mini-review

“…LGPVKLSAEGPT, TAAKTHTVRGFKV, SYFAADRLVP SAG1, GRA2, GRA7 [41] KLFETTDMY, VRQEAIARALARAAA Anopheles mosquito salivary proteins [70] GNIEGQWALKNHSLVSLSEQVLVSCDNIDD CPA (Cysteine peptidase A) [59] YSNIGVCK [71] QTLIAIHTLAIRYAN Paracoccidioides brasiliensis gp43 antigen [72] RPPIFIRRL, sSVRDRLARL EBNA3 [19] Residues 137-160 and 197-211 VP1 gene of foot-and-mouth disease virus [73] (TAKDGMEYYNKMGELYKQ, (RCLLGFKEVGGKCVPASI) Plasmodium knowlesi merozoite surface protein-142 [7] TCPDKKSTA SAG1 (59-67) [9] KSFKDILPK, STFWPCLLR, AVVSLLRLLK, SSAYVFSVK, AMLTAFFLR) SAG1, SAG2, GRA5, SRS52A, GRA6 [17] appropriate adjuvants that can be used along with epitope-based vaccination strategies and establishing optimal immunization protocols along with evaluation criteria.…”